Innoviva (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Business model and strategic pillars

• Operates with three main pillars: resilient royalty streams, a fast-growing specialty therapeutics business (IST), and a portfolio of strategic healthcare assets valued over $700 million as of March.

• Royalties are derived from widely used asthma and COPD treatments, considered highly durable due to strong patents and regulatory complexity.

• IST focuses on infectious disease and critical care, growing at 40–50% annually, with four marketed products and another approved for launch.

• Strategic healthcare assets include innovative companies like Armata (bacteriophage specialist), Syndeio (neuroscience platform), and Linx (drug delivery), offering asymmetric risk-reward profiles.

• The diversified model provides downside protection via royalties and cash, while enabling growth through IST and strategic assets.

Royalty business performance and outlook

• Royalties have shown resilience across market cycles, including during COVID, and are protected by patents and regulatory barriers.

• Revenue is geographically diversified: one-third from the U.S., two-thirds from ex-U.S. markets, providing stability.

• Consensus estimates project about $1 billion in royalty revenues over the next five years.

• Competition in the asthma and COPD space remains stable, with the company insulated from innovation targeting more advanced patient populations.

IST business growth and product launches

• IST is a commercial-stage platform built through acquisitions, with strong clinical evidence and commercial execution driving growth.

• U.S. revenue guidance for IST is $150 million by 2026, with Q1 revenue at $34 million, reflecting strong year-over-year growth.

• Key products include XACDURO (for hospital-acquired pneumonia) and GIAPREZA (for septic shock), both showing robust adoption and growth.

• XACDURO sales more than doubled last year; GIAPREZA continues to expand in both existing and new hospitals.

• NUZOLVENCE, targeting the gonorrhea market, is expected to launch in the second half of the year, with significant long-term potential.